所有图片(2)
别名:
MK-2764 tosylate, (4S,4aS,5aR,12aS)-4,7-bis(Dimethylamino)-9-(2,2-dimethylpropylaminomethyl)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12aoctahydrotetracene-2-carboxamide, 4-methylbenzenesulfonate, Amadacycline tosylate, BAY 73-7388 tosylate, MK 2764 tosylate, MK2764 tosylate, PTK 0796 tosylate, PTK-0796 tosylate, PTK0796 tosylate
经验公式（希尔记法）:
C29H40N4O7·C7H8O3S
推荐产品
质量水平
检测方案
≥97% (HPLC)
形式
powder
储存条件
desiccated
颜色
yellow to orange
溶解性
H2O: 2 mg/mL, clear
储存温度
-10 to -25°C
生化/生理作用
Omadacycline (amadacycline, PTK 0796) is an orally active, potent tetracycline-class antibacterial against broad gram-positive and some gram-negative bacteria, including strains expressing the two main forms of tetracycline resistance (efflux and ribosomal protection). Omadacycline is also active against Haemophilus influenzae (H. influenzae) and atypical and anaerobic pathogens, including Legionella pneumophila, Mycoplasma spp., Ureaplasma spp., Bacteroides spp., and Clostridioides difficile. Unlike tetracycline, Omadacycline is active in vitro in the presence of the ribosomal protection protein Tet(O), despite its ribosomal binding site is similar to that of tetracycline.
注意
Hygroscopic
警示用语：
Warning
危险声明
危险分类
Lact. - Repr. 2
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
Mechanism of action of the novel aminomethylcycline antibiotic omadacycline
Antimicrobial Agents and Chemotherapy, 58(3), 1279-1283 (2014)
James A Karlowsky et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 69(Suppl 1), S6-S15 (2019-08-02)
Omadacycline is a novel aminomethylcycline antimicrobial and semisynthetic derivative of tetracycline. In vitro, omadacycline displays potent activity against gram-positive and many gram-negative bacteria, including methicillin-resistant Staphylococcus aureus, Streptococcus pneumoniae, β-hemolytic streptococci, vancomycin-resistant Enterococcus, and Enterobacteriaceae. Omadacycline is also active against
A B Macone et al.
Antimicrobial agents and chemotherapy, 58(2), 1127-1135 (2013-12-04)
Omadacycline is the first intravenous and oral 9-aminomethylcycline in clinical development for use against multiple infectious diseases including acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), and urinary tract infections (UTI). The comparative in vitro activity
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门